M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)

Inclusion Criteria:

- Histologically confirmed diagnosis of advanced NSCLC

- Have not received prior systemic therapy treatment for their advanced/Stage four
NSCLC. Completion of treatment with cytotoxic chemotherapy, biological therapy, and/or
radiation as part of neoadjuvant/adjuvant therapy is allowed as long as therapy was
completed at least 6 months prior to the diagnosis of metastatic disease. Confirmation
of resolution of toxic effects of previous neoadjuvant/adjuvant chemotherapy therapy
to Grade less than or equal to 1. For radiation toxicity or prior major surgeries,
participants should have recovered from side effects and/or complications.

- Have measurable disease based on RECIST 1.1

- Have a life expectancy of at least 3 months

- Availability of either tumor archival material (less than 6 months old) or fresh
biopsies collected within 28 days (excluding bone biopsies) before the first dose is
mandatory to determine PD-L1 expression level prior to enrollment

- PD-L1 high status as determined by central PD-L1 test or by prior testing using PD-L1
immunohistochemistry 22C3 pharmDx assay

- Other protocol defined inclusion criteria could apply

Exclusion Criteria:

- The participant's tumor harbors an epidermal growth factor receptor (EGFR) sensitizing
(activating) mutation, anaplastic lymphoma kinase (ALK) translocation, ROS1
rearrangement, or BRAF V600E mutation, if targeted therapy is locally approved

- Has received major surgery within 4 weeks prior to the first dose of study
intervention; received thoracic radiation therapy of greater than 30 units of gray
(Gy) within 6 months prior to the first dose of study

- Known severe hypersensitivity to investigational products (M7824 or pembrolizumab), or
any components in their formulations

- Previous malignant disease (other than the target malignancy to be investigated in
this study) within the last 3 years

- Other protocol defined exclusion criteria could apply